vTv Therapeutics just reported Q1 2026 results that blew past every estimate on the Street, landing EPS of $1.65 against a consensus of -$0.10 and revenue of $36.8M against a $20M forecast — and the timing couldn't be more awkward for the short sellers who spent the past month aggressively building their positions.
Short interest has been one of the more notable recent trends on this small-cap biotech. It climbed 44% over the past week alone, rising to roughly 3.5% of the free float. Over the past month the position doubled in size, with shares short jumping 75%. The pace of that build — concentrated almost entirely in the final two weeks of April and into May — points to pre-earnings bearish conviction that the Q1 print just dismantled. The ORTEX short score ticked up to 51.5 as of Tuesday, its highest in at least two weeks, having risen steadily from 42.4 on May 1. That momentum was building the wrong way for shorts heading into the release. Yet the borrow market itself never got particularly stressed: cost to borrow is running at just 4.1% and availability remains ample, meaning the lending pool has plenty of room — there are no structural signs of a squeeze in the mechanics, even if the news flow creates a painful mark-to-market.
The Street had been quietly constructive on cadisegliatin, vTv's lead diabetes candidate, well before this print. Six analysts carry Buy ratings. The most recent initiations — Evercore ISI in March, BTIG and Roth Capital in the months prior — collectively set targets ranging from $44 to $58, implying meaningful upside even from current levels of $32.11. TD Cowen's January initiation carried a $67 target, the most bullish on the board, though that level sits well above the current stock price and should be read in the context of the trial at the time rather than as a near-term anchor. The bull case centres on cadisegliatin addressing a genuine unmet need in Type 1 diabetes, with optionality into Type 2. Bears have focused on clinical risk and the company's reliance on external partnerships to fund the pipeline — a concern the revenue beat directly challenges, given $36.8M in Q1 revenue far exceeded what a development-stage company would typically generate.
Institutional ownership adds an interesting dimension. Millennium Management disclosed a position of 225,073 shares as of mid-April, representing nearly all of its current stake as new money — it held essentially nothing before. The JDRF T1D Fund and Breakthrough T1D each reported new positions of 215,692 shares in early April, which is notable: mission-driven capital from diabetes-focused organisations taking a meaningful stake alongside traditional funds signals genuine belief in the clinical story. MacAndrews & Forbes remains the anchor holder at 12% of shares. Fidelity added roughly 76,000 shares through February, and Vanguard added 41,000 through March, suggesting passive and active flows have both been moving in the same direction.
Historical earnings reactions at vTv have been directionally positive. The two most recent prints each produced next-day gains — +13.1% in March 2026 and +7.5% in November 2025. The five-day reaction following November's Q3 result was even stronger at +29%. The one exception in the sample was a -3.9% move on a separate March event. The pattern is not consistent enough to be predictive, but it does reflect that positive surprises at this company have typically been rewarded with multi-day momentum rather than single-session spikes.
With the Q1 beat now public and a 424B2 filing — indicating a secondary offering — hitting the SEC wire on the same evening as the results, the next focus shifts to how the company intends to deploy fresh capital, whether cadisegliatin's clinical programme timeline has shifted, and whether the large short position built over the past month begins to unwind or firms up as investors digest the offering terms.
See the live data behind this article on ORTEX.
Open VTVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
